AI/ML Innovations Inc. Enters Binding Letter of Intent to Acquire Strategic Neural Net Healthcare Assets
AI/ML Innovations Inc. Enters Binding Letter of Intent to Acquire Strategic Neural Net Healthcare Assets
Naiad's proprietary Long ECG Neural Net (L-ECG NN) - An accurate and efficient method to read and label long ECGs. The L-ECG NN can label an entire 48-hour long ECG file in less than 5 minutes, while conventional methods take a couple of weeks.Highlights:
亮点：
- Strategic Expansion and Market Growth: AI/ML Innovations Inc. expands its portfolio by acquiring Naiad Labs Inc. Product Division.
- AI-driven Strategic Healthcare Assets: The purchase includes a proprietary "Long ECG Neural Net", reducing the reading and labeling of long ECGs from a couple of weeks to under 5 minutes.
- 战略扩张和市场增长：AI/ML Innovations Inc.通过收购Naiad Labs Inc.产品部门扩大其产品组合。
- 人工智能驱动的战略医疗资产：此次收购包括专有的 “长心电神经网络”，将长心电图的读取和标签从几周缩短到不到5分钟。
VICTORIA, BC / ACCESSWIRE / May 2, 2024 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce a significant milestone in the signing of a binding Letter of Intent (the "LOI") dated April 27, 2024 to purchase Naiad Labs' Product Division, subject to certain terms and conditions.
不列颠哥伦比亚省维多利亚州/ACCESSWIRE /2024年5月2日/ AI/ML Innovations Inc.（“AIML” 或 “公司”）（CSE: AIML）（OTCQB: AIML）（OTCQB: AIML）（FWB: 42FB）是一家致力于收购和推进满足紧急社会需求的人工智能/机器学习技术的领先公司，很高兴地宣布签署具有约束力的意向书（“LOVE”）是一个重要的里程碑 I”）于2024年4月27日收购Naiad Labs的产品部，但须遵守某些条款和条件。
The Acquired Assets include:
收购的资产包括：
Naiad's proprietary Long ECG Neural Net (L-ECG NN) - An accurate and efficient method to read and label long ECGs. The L-ECG NN can label an entire 48-hour long ECG file in less than 5 minutes, while conventional methods take a couple of weeks.
Naiad 专有的长心电神经网络 (L-ECG NN)-一种读取和标记长心电图的准确而有效的方法。L-ECG NN 可以在不到 5 分钟的时间内标记整个 48 小时的心电图文件，而传统方法则需要几周的时间。
The Neural Network Store (NNStore) - A subscription-based online neural net store that allows device company developers and researchers to upload files for analysis by various AI systems.
神经网络商店 (nnStore)-一种基于订阅的在线神经网络商店，允许设备公司的开发人员和研究人员上传文件供各种 AI 系统分析。
Paul Duffy, CEO of AIML, added, "We are very excited by this acquisition, as we see great synergy between these newly acquired technologies and our current Follow Your Heart suite of products". Duffy continues, "Moreover, the Neural Net Store expands our reach, offering our Neural Nets as a Service to the broad and growing community of smart sensor wearables and end user applications.'"
AIML首席执行官保罗·达菲补充说：“我们对这次收购感到非常兴奋，因为我们看到了这些新收购的技术与我们目前的Follow Your Heart产品套件之间的巨大协同作用”。达菲继续说：“此外，神经网络商店扩大了我们的覆盖范围，为广泛且不断增长的智能传感器可穿戴设备和最终用户应用程序社区提供我们的神经网络即服务。”
The salient terms of the LOI include:
意向书的主要条款包括：
| 1. | AIML will purchase 100% of Naiad's Long ECG Neural Net, 100% of Naiad's Neural Net Store & NNaaS, and access to certain contracted services to be provided by Naiad's management and technical team on an ongoing basis under separate employment/consulting agreements (collectively, the "Assets"). | |
| 2. | AIML will issue 6,700,000 Common Shares from its Treasury to Naiad, (currently valued at $469,000), as full and final payment for the Assets. The shares will be subject to a 12-month hold period. | |
| 3. | AIML will create a new operating subsidiary which shall hold the Assets. | |
| 4. | AIML will pay a streaming royalty (the "Royalty") to Naiad for up to a 20-year period, as per the following terms: | |
| i. | a 2% Royalty which is payable on gross revenue of not less than $1,500,000 and not greater than $5,000,000 inclusive per fiscal year, if and only if such revenue is directly attributable to third-party licensing of the Long ECG Neural Net, AND | |
| ii. | a 3% Royalty which is payable on all gross revenue above $5,000,000 per fiscal year, if and only if such revenue is directly attributable to third-party licensing of the Long ECG Neural Net. | |
| iii. | AIML at its sole discretion may purchase the Royalty from Naiad at any time for $1,000,000. | |
| 5. | AIML will grant a total of 700,000 stock options for 5 years at a $0.20 exercise price to management members of Naiad, in accordance with the Corporation's Stock Option Plan. | |
| 6. | a 3% Royalty which is payable on all gross revenue above $5,000,000 per fiscal year, if and only if such revenue is directly attributable to third-party licensing of the Long ECG Neural Net. | |
| 7. | AIML at its sole discretion may purchase the Royalty from Naiad at any time for $1,000,000. | |
| i. | the Long ECG Neural Net has formally entered the US FDA approval process; AND, | |
| ii. | The Long ECG Neural Net generates gross revenue of not less than $1,000,000. | |
| 1。 | AIML将购买Naiad的长心电神经网络的100％，Naiad神经网络商店和NNAA的100％，以及NaaS的某些合同服务，这些服务将由Naiad的管理和技术团队根据单独的雇用/咨询协议（统称为 “资产”）持续提供。 | |
| 2。 | AIML将从其财政部向奈亚德发行6,700,000股普通股（目前价值46.9万美元），作为资产的全额和最后一笔付款。这些股票将有12个月的持有期。 | |
| 3. | AIML将创建一个新的运营子公司，该子公司将持有资产。 | |
| 4。 | 根据以下条款，AIML将向Naiad支付长达20年的流媒体特许权使用费（“特许权使用费”）： | |
| 我。 | 当且仅当该收入直接归因于长心电神经网络的第三方许可时，每财年的总收入不少于1,500,000美元且不超过5,000,000美元（含），则应支付2％的特许权使用费，以及 | |
| ii。 | 当且仅当此类收入直接归因于长心电神经网络的第三方许可时，每财年总收入超过5,000,000美元即可支付3％的特许权使用费。 | |
| iii。 | AIML可随时自行决定以100万美元的价格从Naiad购买特许权使用费。 | |
| 5。 | 根据公司的股票期权计划，AIML将以0.20美元的行使价向Naiad的管理成员授予总共70万份为期5年的股票期权。 | |
| 6。 | 当且仅当此类收入直接归因于长心电神经网络的第三方许可时，每财年总收入超过5,000,000美元即可支付3％的特许权使用费。 | |
| 7。 | AIML可随时自行决定以100万美元的价格从Naiad购买特许权使用费。 | |
| 我。 | 长心电神经网络已正式进入美国食品药品管理局的批准程序；而且， | |
| ii。 | 长心电神经网络产生的总收入不少于1,000,000美元。 | |
The Assets Purchase has a non-arm's length component to it in that AIML's Interim CPO, Esmat Naikyar, is the CEO and co-Founder of Naiad Labs Inc. Mr. Naikyar is neither on the board of directors of AIML, nor will he be involved in AIML's approval process.
此次资产收购有非公平的组成部分，因为AIML的临时首席财务官埃斯马特·奈克亚尔是Naiad Labs Inc.的首席执行官兼联合创始人。奈克亚尔先生既不是AIML的董事会成员，也不会参与AIML的批准程序。
The closing of the Asset Purchase is subject to satisfactory completion of due diligence by AIML, AIML Board approval, any requisite regulatory approval, and other conditions typically set out in a purchase and sale agreement of this type. The parties are working to complete a definitive agreement based upon the terms found of LOI on or about May 30, 2024.
资产收购的完成取决于AIML令人满意地完成尽职调查、AIML董事会批准、任何必要的监管批准以及此类买卖协议中通常规定的其他条件。双方正在努力根据2024年5月30日左右的意向书条款完成最终协议。
No Finder's Fee will be paid in conjunction with this transaction. The Asset Purchase will not result in either a change of control or the creation of new control persons.
本次交易不会同时支付任何发现者费用。资产购买不会导致控制权的变更或新的控制人员的设立。
###
###
About AI/ML Innovations Inc.
关于 AI/ML Innovations Inc.
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".
AI/ML Innovations Inc.调整了其业务运营，以利用新兴的人工智能（AI）和机器学习（ML）领域，最初的投资重点是新兴的数字健康和福祉公司，这些公司利用人工智能、机器学习、云计算和数字平台推动变革性的医疗管理解决方案和整个健康连续体的精准支持交付。通过与Health Gauge（AIML持有95.2％的股权）、Tech2Heal（高达22％的所有权，目前由AIML持有12.44％的所有权）、AI Rx Inc.（AIML持有70％的股权）以及其他计划中的增值投资，公司继续利用不断扩大的增长领域，使公司所有利益相关者受益。AI/ML的股票在加拿大证券交易所交易，代码为 “AIML”，OTCQB风险投资市场以 “AIMLF” 的形式交易，在法兰克福证券交易所交易的代码为 “42FB”。
On behalf of the Board of Directors
Tim Daniels, Executive Chairman
代表董事会
蒂姆·丹尼尔斯，执行主席
For more information about AI/ML Innovations:
有关 AI/ML 创新的更多信息:
For detailed information please see AI/ML's website or the Company's filed documents at
有关详细信息，请访问AI/ML的网站或公司提交的文件，网址为
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com
欲了解更多信息，请致电 (778) 405-0882 或 info@aiml-innovations.com 与 Blake Fallis 联系
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
CSE及其监管服务提供商（该术语在CSE的政策中定义）均不对本新闻稿的充分性或准确性承担责任。
For AI/ML Innovations Investors
致人工智能/机器学习创新投资者
Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives, and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at .
本新闻稿中发表的某些非基于历史信息的陈述是前瞻性陈述，涉及大量已知和未知的风险和不确定性。本新闻稿包含与AI/ML Innovations对管理层计划、目标和战略（包括捍卫公司知识产权的战略）的预期有关的明示或暗示的前瞻性陈述。这些陈述既不是承诺也不是担保，但存在各种风险和不确定性，其中许多风险和不确定性是我们无法控制的，这可能导致实际结果与这些前瞻性陈述中设想的结果存在重大差异。提醒现有和潜在投资者不要过分依赖这些前瞻性陈述，这些陈述仅代表截至本文发布之日。除非适用的证券法明确要求，否则AI/ML Innovations Inc. 没有义务更新或修改本新闻稿中包含的信息，无论是由于新信息、未来事件或情况还是其他原因。有关不确定性和风险的更多信息，可以在AI/ML向证券监管机构提交的披露文件中找到，网址为。
SOURCE: AI/ML Innovations Inc.
来源：AI/ML Innovations Inc.